Sign Up
HB 6062 Connecticut House · 2025 Regular Session

AN ACT PROHIBITING DIRECT-TO-CONSUMER PRESCRIPTION DRUG ADVERTISEMENTS.

HB 6062 prohibits businesses in Connecticut from directly advertising prescription drugs (drugs requiring a prescription under state or federal law) to individual consumers within the state. It affects pharmaceutical companies, pharmacies, and other entities selling prescription drugs, but allows pharmaceutical manufacturers registered with the Department of Consumer Protection to promote these drugs directly to doctors and other prescribing practitioners. Violations would be treated as unfair trade practices under Connecticut law, requiring the state to hire additional staff for enforcement (estimated cost: $165,000 in fiscal year 2026). The law takes effect on October 1, 2025.
Issues: ✓ HealthcareSupports HealthcareProhibits misleading direct drug ads to consumers, protecting patient decision-making and aligning with patient rights in healthcare policy.90% confidence
Bill status in committee 1 of 4 stages cleared
Introduction
Jan 2025
Committee Review
Floor Vote
Governor
Introduced Jan 22, 2025 Last action Apr 29, 2025
Maddy AI version diff · 1 comparison

What changed between versions

Proposed Bill → Committee Bill · 4 edits
MODERATE
The bill was moved from the proposed version to the committee version, receiving a new committee number (LCO No. 4609 instead of 2091) and being referred to the Committee on General Law. The substantive policy content remains the same, prohibiting direct-to-consumer prescription drug advertisements in the state, but the committee version adds detailed legal definitions for key terms like 'consumer', 'legend drug', and 'pharmaceutical representative' to clarify the law's application.
Scope change
The bill's scope remains the same - prohibiting direct-to-consumer prescription drug advertisements - but the committee version adds specific definitions to clarify who and what the law applies to.
DEFINITION

Added seven detailed definitions for key terms including 'consumer', 'legend drug', 'person', 'pharmaceutical manufacturer', 'pharmaceutical marketing firm', 'pharmaceutical representative', and 'prescribing practitioner' to clarify the law's application.

ENFORCEMENT

Added language specifying that violations will be treated as unfair or deceptive trade practices under existing consumer protection laws.

REQUIREMENT

Added authority for the Commissioner of Consumer Protection to adopt regulations to implement the new advertising restrictions.

TECHNICAL

Changed the bill number from LCO No. 2091 to LCO No. 4609 and updated the page count from 1 of 1 to 3 of 3 due to added definitions.

Floor votes

How they voted

No floor votes recorded yet.
Full legislative history

Actions timeline

Total actions
13
Key actions
3
Committee
5
Apr 29, 2025
Lower · Passed
REF. BY HOUSE TO COMMITTEE ON Appropriations
lower
Mar 24, 2025
Lower · Passed
Joint Favorable
lower
Feb 13, 2025
Committee
REF. TO JOINT COMM. ON General Law
lower
Feb 11, 2025
Lower · Passed
DRAFTED BY COMMITTEE
lower
Jan 22, 2025
Committee
REF. TO JOINT COMM. ON General Law
lower
0 primary · 0 co-sponsors

Sponsors

No sponsor information available.